Find, compare & contact
Naldemedine API Manufacturers & Suppliers

teaser-1024x654-1
Contact suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Naldemedine is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Naldemedine or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Naldemedine API 916072-89-4?

Description:
Here you will find a list of producers, manufacturers and distributors of Naldemedine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Naldemedine 
Synonyms:
 
Cas Number:
916072-89-4 
DrugBank number:
DB11691 
Unique Ingredient Identifier:
03KSI6WLXH

General Description:

Naldemedine, identified by CAS number 916072-89-4, is a notable compound with significant therapeutic applications. Naldemedine is an opioid receptor antagonist . It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.

Indications:

This drug is primarily indicated for: For the treatment of opioid-induced constipation . Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Naldemedine undergoes metabolic processing primarily in: Naldemedine is mainly metabolized to nor-naldemedine by CYP3A . Some metabolism to naldemedine-3-glucuronide occurs via UGT1A3. Both metabolites are acitive but less potent than naldemedine. The relative exposures of these metabolites are 9-13% and <3% for nor-naldemedine and naldemedine-3-glucuronide respectively. Naldemedine is also cleaved in the intestine to form benzamidine and naldemedine carboxylic acid. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Naldemedine are crucial for its therapeutic efficacy: Tmax is 0.75 h . Administration with a high-fat meal reduces Cmax by 35% and increases Tmax to 2.5 h. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Naldemedine is an important consideration for its dosing schedule: The terminal elimination half life is 11 h . This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Naldemedine exhibits a strong affinity for binding with plasma proteins: Naldemedine is 93-94% bound to human plasma proteins . This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Naldemedine from the body primarily occurs through: 57% of naldemedine is excreted in the urine with 16-18% as the parent compound and 35% is excreted in the feces . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Naldemedine is distributed throughout the body with a volume of distribution of: The apparent volume of disribution during the terminal phase is 155 L. This metric indicates how extensively the drug permeates into body tissues.

Pharmacodynamics:

Naldemedine exerts its therapeutic effects through: Naldemedine is an opioid receptor antagonist with restricted movement across the blood brain barrier . This allows it to antagonize the periperal effects of opioid drugs such as constipation without interfering with the effects on the central nervous system. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Naldemedine functions by: Naldemedine binds to and antagonizes mu-, delta-, and kappa-opioid receptors . The binding of opioid agonists to peripheral mu-opioid receptors slows the transit of feces through the intestine resulting in constipation. By antagonizing mu-opioid receptors, naldemedine inhibits this effect. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Naldemedine belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic, classified under the direct parent group Morphinans. This compound is a part of the Organic compounds, falling under the Alkaloids and derivatives superclass, and categorized within the Morphinans class, specifically within the None subclass.

Categories:

Naldemedine is categorized under the following therapeutic classes: Alimentary Tract and Metabolism, Alkaloids, Drugs for Constipation, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Morphinans, Opiate Alkaloids, Opioid Antagonists, Peripheral Opioid Receptor Antagonists, Phenanthrenes, UGT1A3 substrates. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Naldemedine include:

  • Water Solubility: Slightly soluble

Naldemedine is a type of Other substances


The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.

Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.

Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.

Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.

In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.